Intelsat’s Global, Multi-Layered High-Throughput FlexMaritime Service Expands Into Indian Territorial Waters
22.11.2021 13:00:00 EET | Business Wire | Press release
Intelsat, operator of the world's largest integrated satellite and terrestrial network, announces the expansion of its global FlexMaritime service, now enabling connectivity for vessels traveling in Indian territorial waters and immediately enhancing the service coverage for all of Intelsat’s 8,000 existing FlexMaritime vessels. The landmark development also provides access for Indian-registered vessels to Intelsat’s award-winning global high-throughput maritime network. Intelsat's expansion is made possible by a new in-country gateway that is operationally ready to provide service via Intelsat’s HTS satellites under India-based partner Cloudcast's In-Flight and Maritime Connectivity (IFMC) license.
FlexMaritime provides high-speed, resilient connectivity service with 99.95% proven network uptime. The expansion of FlexMaritime into India will open new business opportunities and accelerate digital transformation for thousands of Indian-flagged vessels and ships trading in Indian territorial waters. According to the Ministry of Shipping, around 95% of India's trading by volume and 70% by value is done through maritime transport.
"The completion of this regulatory milestone means customers of our FlexMaritime solutions partners will immediately benefit from the well-known power, performance and resilience of the FlexMaritime service in Indian waters," said Intelsat Senior Vice President of Mobility, Mark Rasmussen. "The network expansion also demonstrates Intelsat's commitment to mobility services providing yet another new dimension of global trade with access for Indian companies."
Intelsat has experienced continued growth in its FlexMaritime service. More than 8,000 vessels benefit from unrivaled network density and a global, multi-layered high-throughput satellite (HTS) fabric that enables partners to create unique service packages at enterprise-grade performance levels. With terminal sizes of 37cm, 45cm, 60cm and 1 meter, FlexMaritime meets the connectivity needs of every type of vessel with scale and global reach, even in high-traffic port locations.
The gateway will be located in Noida, India, serving as a critical link between Intelsat's terrestrial ground network and space assets and extending Intelsat's existing global network to a vital trading port.
Services are slated for availability at the beginning of 2022 through Intelsat's many solutions partners.
About Intelsat
As the foundational architects of satellite technology, Intelsat operates the world's most trusted satellite telecom network. We apply our unparalleled expertise and global scale to connect people, businesses and communities, no matter how difficult the challenge. Intelsat is building the future of global communications with the world's first hybrid, multi-orbit, software-defined 5G network designed for simple, seamless, and secure coverage precisely when and where our customers most need it. Follow the leader in global connectivity and "Imagine Here," with us, at Intelsat.com.
About Cloudcast
Cloudcast is a 100% subsidiary of Planetcast Media Services Limited and is focused on growing the business in satellite communications and promoting excellence in Value Added Services, Business Practices, Technology and Operations. Cloudcast has commercial licenses for VSAT, ISP, and the new IFMC Gateway Services in India. Planetcast, the parent company, has over the years been instrumental in providing cutting-edge technology to enhance broadcast services. The Planetcast Group's ability to conceptualize, architect, and implement new and expanded capabilities allows clients to take their business to the next level. It is a key market player in providing technology-led managed services to the broadcasting industry in India.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211122005896/en/
Contact information
Media:
Melissa Longo - melissa.longo@intelsat.com; +1 240-308-1881
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom